Overview

Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

Status:
Completed
Trial end date:
2003-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).
Phase:
Phase 2
Details
Lead Sponsor:
EMD Serono
Treatments:
Levodopa